We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Assura Plc | LSE:AGR | London | Ordinary Share | GB00BVGBWW93 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.12 | 0.31% | 39.12 | 3,770,360 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 39.08 | 39.14 | 39.26 | 38.84 | 38.84 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 157.8M | -28.8M | -0.0089 | -43.98 | 1.26B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:24 | UT | 1,504,777 | 39.12 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/12/2024 | 08:30 | UK RNS | Assura PLC Director/PDMR Shareholding |
| 03/12/2024 | 07:00 | UK RNS | Assura PLC Notice of Dividend |
| 14/11/2024 | 13:00 | UK RNS | Assura PLC Director/PDMR Shareholding |
| 14/11/2024 | 11:04 | ALNC |  TOP NEWS: Assura to list in Johannesburg as turns to profit; payout up |
| 14/11/2024 | 07:00 | UK RNS | Assura PLC Assura Plc Interim Results |
| 14/11/2024 | 07:00 | UK RNS | Assura PLC Confirmation of secondary listing on the JSE |
| 08/11/2024 | 09:07 | UK RNS | Assura PLC Director/PDMR Shareholding |
| 31/10/2024 | 07:00 | UK RNS | Assura PLC Notice of Results & Retail Investor Presentation |
| 31/10/2024 | 07:00 | UK RNS | Assura PLC Total Voting Rights |
| 28/10/2024 | 09:08 | ALNC | UK healthcare property investor Assura set to list in Johannesburg |
Assura (AGR) Share Charts1 Year Assura Chart |
|
1 Month Assura Chart |
Intraday Assura Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 14/12/2024 08:20 by Assura Daily Update Assura Plc is listed in the Real Estate Agents & Mgrs sector of the London Stock Exchange with ticker AGR. The last closing price for Assura was 39p.Assura currently has 3,236,951,244 shares in issue. The market capitalisation of Assura is £1,266,942,717. Assura has a price to earnings ratio (PE ratio) of -43.98. This morning AGR shares opened at 38.84p |
Posted at 15/11/2024 13:00 by alotto How many people will take the scrip shares in lieu of dividend though?It's quite a strange option that give shareholders consider the soft share price |
Posted at 14/11/2024 16:41 by dandigirl Thank you for the NTA figure. Maybe a stonking buy for those new to the share and content for it to hover around 40p, maybe, and receive the income. We have a lot already showing a substantial loss and few signs that there will any meaningful share price gains anytime soon. The management have touted their deals as significant events. For them, probably a reason to seek increased remuneration. For shareholders they are not. The share price started the year at 48.12. As I write it is 38.88, down nearly 10%. I see further falls as the budget measures start to bite. |
Posted at 06/11/2024 16:54 by alotto Who in their right mind would buy a gov bond at 4.3% when you can get here 8% plus very likely capital appreciation? Something else is going on. Either a stampede or suspicion of something fundamentally wrong.Debt generally makes me nervous but the assets, the almost certain rental income and the A- rating reassure me. No idea how to read the share price. Probably a stampede. |
Posted at 06/11/2024 16:29 by goliard Dear me this share price performance is awful and I'm not even seeing it as a buying opportunity (which probably means it is a buying opportunity). Nothing really wrong with the company, but everything wrong with the gilt market and driving this down. Just wondering where it stops now. |
Posted at 01/11/2024 13:29 by alotto So they are doing the needful to promote a higher share price.I'm not sure about the reasons for a South African dual listing though. |
Posted at 01/11/2024 12:39 by justiceforthemany Well the CEO and CFO alone hold more than 4 MILLION shares between them. Plenty of incentive to get the share price motoring back to 60-70p. |
Posted at 11/9/2024 06:27 by goliard Weak growth figures today should mean a higher chance of interest rate cuts and that should mean a boost to AGR price... but let's see. |
Posted at 05/9/2024 08:54 by this_is_me AGR looks like better value than PHP at current share prices. I bought to hold long term for the dividend but, of course, that doesn't mean that I will not sell if the share price goes way up. |
Posted at 30/6/2024 22:05 by kernelthread Unless I'm missing something, paying a dividend in scrip is equivalent to not paying a dividend at all. The total number of shares per se is irrelevant; all that matters is what proportion of the total equity in the company is owned by a particular shareholder. For example, if you doubled the total number of shares in the company but also doubled the holding of each shareholder (i.e. 2 to 1 share split), the share price would halve but the total value of everyone's holding stays constant, as does the dividend they receive (dividend per share halves, but they have twice as many shares). Paying a dividend in scrip increases each shareholder's holding by the same factor of F = (1 + y/100) where y is the yield in %. So each share is worth (1/F) times what it was before, but each holder has F times as many shares, so total value is the same. The share price can be expected to drop by a factor of F. Nobody receives any cash (except for some 'financial friction' in the form of brokers etc. paid to issue the RNSs and update records of how many shares in circulation and who owns them). |
Posted at 22/5/2024 08:44 by george stobart Jefferies Note - Wednesday, May 22, 2024FY24: Not Quite a Clean Bill of Health - PT 45p and cut to Hold LTV is 43% with the new JV, but more action is needed to allay the risk a credit cut. Options include an equity injection (shares trade at 13% disc to NAV), asset disposals (earnings dilutive by c. 300-400bps) and curtail development (AGR is being priced out). Our PT is cut to 45p factoring in the dilutive impact of £200m (Jef Est) pa high yield/low growth asset sales to degear to 30% but the 7.8% DY risks being uncovered (FY25 1x). The shares are cut to Hold. Earnings & Dividends: In FY24 net rents were +4% to £143.3m with average reviews +3.9% (FY23: 3.8%) governed by the district valuer, the commercial arm of the Valuation Office Agency which advises the NHS on valuations, rent reviews and rents on new developments. Vacancies are 1% (unch) and the contracted rent roll £150.6m pa, rising to an all up £161m on developments and reviews. Admin was £13.2m with an EPRA Cost Ratio (incl & excl vacancy costs) 13.2% and 11.7% resp. (FY23: 13.5% & 12.3%). EPS was flat at 3.4p (FY23: 3.3p) and +5% DPS 3.26p, below the 10yr CAGR of 7.3%. Portfolio Performance: Revalued at £2708m on NIY of +30bps to 5.17% after a -4% Lfl w/down (FY23 -6.4%) partly offset by value activity. The NAV was -8% to 49.4p but the spread wide at NIYs 3.8%-8.5% (equiv 3.9%-8.5% so there is thin organic growth) with the valuer's ERV assumptions £100-£750/sqm (FY23: £100-£669/sqm). The new 15yr life JV with USS diversifies funding and will be seeded with seven (no development, long dated, index linked) assets from AGR valued at £107m at an undisclosed discount. The JV will target acquisition-led growth to £250m with AGR retaining a 20% stake with a management fee. Development Programme: AGR does not disclose target returns and five schemes were completed with a value of £71.8m in a mix of GP surgeries and broader healthcare markets. Three new schemes are underway with two in Ireland and one in Bury St Edmunds, making eight schemes on site with a combined development cost of £91.2m with £42m remaining to spend. Higher construction and financing costs are affecting the pipeline as AGR needs c 30% higher rents to be viable and thus schemes are being postponed. Financial Position: Net debt is £1.2bn (all unsecured) at a kd of 2.3% (unch, all fixed) and termed 6yrs. Over the next four years, £170m of debt needs refinancing which at 5.5% would impact EPS by -6%. Gearing is, we maintain, too high and risks cut from Fitch A-. The net debt/EBITDA ratio at 9.4x is >9x Fitch’s rating sensitivity, and 4-5x looks more appropriate. The LTV at 45% is elevated after two years of portfolio w/downs and can operate in the range 40-50% but we view <40% as appropriate. The 3% 2028 bond (Ex 1 traded above its issue spread in 2023. Outlook: CEO Jonathan Murphy: "The long-term partnership aligns with cross-party political support for investment into essential NHS community healthcare buildings.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
